despit
mani
year
research
human
dna
vaccin
yet
fulfil
earli
promis
past
year
multipl
gener
dna
vaccin
develop
test
preclin
model
prophylact
therapeut
applic
area
infecti
diseas
cancer
fail
clinic
thu
dna
vaccin
achiev
success
licensur
veterinari
applic
poor
immunogen
human
compar
tradit
proteinbas
vaccin
hinder
progress
mani
strategi
attempt
improv
dna
vaccin
potenc
includ
use
effici
promot
codon
optim
addit
tradit
genet
adjuv
electropor
intraderm
deliveri
variou
primeboost
strategi
review
summar
advanc
dna
vaccin
technolog
attempt
answer
question
dna
vaccin
might
eventu
licens
human
use
dna
vaccin
compos
bacteri
plasmid
encod
antigen
interest
control
strong
eukaryot
promot
cmv
intron
host
cell
transfect
varieti
rout
includ
inject
plasmid
muscl
dermi
mucos
applic
dna
vaccin
present
rang
advantag
box
convent
live
viru
protein
subunit
vaccin
enabl
antigen
express
apc
process
present
epitop
antigen
mhc
class
ii
molecul
therebi
induc
cellular
immun
plasmid
prepar
rapid
cost
effect
compar
recombin
protein
suffer
problem
improp
protein
fold
dna
highli
stabl
flexibl
allow
easi
modif
plasmid
sequenc
may
relev
exampl
pandem
speed
vaccin
design
paramount
last
year
dna
vaccin
prove
effect
anim
model
includ
hiv
malaria
influenza
dna
vaccin
extens
evalu
human
recent
review
identifi
phase
phase
ii
two
phase
iii
human
trial
dna
vaccin
good
safeti
record
common
advers
reaction
mildmoder
inflamm
associ
pain
red
swell
inject
site
howev
consist
theme
human
dna
vaccin
trial
suboptim
immunogen
compar
tradit
proteinbas
vaccin
approach
find
human
applic
strategi
need
found
enhanc
dna
vaccin
immunogen
option
enhanc
immunogen
includ
strategi
optim
cellular
uptak
plasmid
electropor
coexpress
plasmid
encod
adjuv
cytokineencod
gene
coformul
dna
vaccin
tradit
adjuv
compound
codon
optim
maxim
protein
express
boost
dna
vaccin
live
viral
vector
adjuv
protein
vaccin
needless
say
ongo
challeng
lack
knowledg
immunogen
need
provid
protect
particular
diseas
cancer
without
surrog
measur
vaccin
efficaci
requir
level
immunogen
known
success
outcom
studi
achiev
similar
challeng
face
tcell
vaccin
field
recent
licensur
dna
vaccin
veterinari
applic
includ
west
nile
viru
hors
infecti
hematopoiet
necrosi
factor
diseas
salmon
melanoma
dog
reinforc
view
recent
technolog
breakthrough
effect
human
dna
vaccin
may
within
reach
unlik
occur
without
research
advanc
better
understand
dna
vaccin
action
particular
enhanc
immunogen
also
better
model
accur
assess
compar
dna
vaccin
effect
desper
need
ongo
problem
dna
vaccin
field
poor
abil
predict
human
vaccin
respons
base
mous
immunogen
data
mean
quantit
differ
seen
differ
adjuv
dna
vaccin
approach
mice
rare
translat
human
goldstandard
efficaci
assess
remain
human
nonhuman
primat
adjuv
compar
studi
standard
nonadjuv
dna
vaccin
unfortun
cost
impedi
includ
commerci
constraint
mean
studi
undertaken
refer
made
text
comparison
adjuv
dna
vaccin
unless
state
otherwis
refer
comparison
dna
vaccin
without
addit
adjuv
case
referenc
dna
vaccin
comparison
undertaken
mice
qualit
rather
quantit
differ
individu
studi
note
sinc
quantit
differ
influenc
larg
number
studyspecif
variabl
therefor
compar
studi
event
unlik
predict
human
respons
follow
intramuscular
inject
plasmid
dna
taken
muscl
cell
monocyt
express
antigen
antigen
peptid
load
mhci
molecul
muscl
cell
mhci
mhcii
molecul
apc
apc
may
also
captur
protein
secret
transfect
cell
contain
transfect
apoptot
muscl
cell
antigenload
apc
traffic
drain
lymph
node
activ
b
cell
cell
figur
sinc
amount
antigen
express
small
order
nanogram
picogram
immunogen
depend
upon
help
cpg
motif
plasmid
backbon
play
role
builtin
adjuv
promot
induct
tcell
respons
core
cpg
motif
consist
unmethyl
cpg
flank
two
purin
two
yrimidin
cpg
site
rel
rare
vertebr
comparison
bacteri
genom
viral
dna
tolllik
receptor
tlr
express
endosom
apc
includ
dc
b
cell
upon
recognit
cpg
trigger
signal
cascad
result
proinflammatori
respons
bind
nucleic
acid
requir
cpgactiv
innat
immun
respons
cpg
motif
therebi
increas
immunogen
dna
vaccin
although
recent
shown
sole
mediat
adjuv
effect
knockout
mice
still
respond
dna
vaccin
plasmid
dna
doublestrand
structur
interact
cytoplasm
dna
sensor
sting
therebi
activ
tlrindepend
pathway
induc
type
interferon
unlik
activ
cpg
motif
methyl
dsdna
alter
activ
rather
poli
dadt
poli
dtda
induc
higher
level
compar
poli
dgdc
dcdg
suggest
righthand
helic
structur
bform
dna
essenti
cellular
activ
product
induc
via
pathway
found
crucial
direct
indirect
antigen
present
via
dc
muscl
cell
respect
recent
helicas
identifi
new
intracellular
dna
sensor
myeloid
dc
bound
dna
sting
local
togeth
cytosol
knockdown
express
block
activ
bform
dna
addit
rigi
describ
sens
cytosol
bform
dna
via
rna
polymeras
iii
trigger
respons
transcript
factor
furthermor
sens
cytosol
bform
dna
activ
inflammasom
respons
via
adaptor
apoptosisassoci
specklik
protein
recent
research
reveal
plethora
endosom
cytoplasm
dna
sensor
may
recogn
plasmid
dna
henc
contribut
immunogen
dna
vaccin
new
knowledg
therebi
creat
opportun
exploit
mechan
enhanc
dna
vaccin
immunogen
preclin
vaccin
safeti
evalu
includ
assess
local
reactogen
system
toxic
plu
histopatholog
appropri
anim
model
one
initi
safeti
concern
dna
vaccin
risk
integr
partial
complet
plasmid
sequenc
host
genom
insert
mutagenesi
therebi
risk
inactiv
tumor
suppressor
gene
activ
oncogen
caus
chromosom
instabl
break
rearrang
fortun
concern
realiz
experiment
data
show
rate
plasmid
integr
neglig
lower
spontan
rate
mutat
mammalian
genom
dna
inject
rare
result
longterm
persist
plasmid
tissu
distal
site
vaccin
administr
howev
plasmid
modifi
backbon
enhanc
gene
express
modifi
new
deliveri
method
may
increas
risk
integr
need
evalu
persist
plasmid
dna
clinic
use
safeti
issu
includ
possibl
dna
vaccin
could
stimul
product
antidna
antibodi
associ
autoimmun
disord
system
lupu
erythematosu
data
anim
studi
show
dna
vaccin
could
increas
product
antidna
autoantibodi
increas
diseas
sever
lupuspron
anim
induc
autoimmun
healthi
anim
inject
mice
plasmid
encod
hepat
b
surfac
antigen
hbsag
induc
liver
kidney
damag
explain
prolong
express
hbsag
result
format
immun
complex
parker
et
al
fail
find
evid
patholog
chang
repeat
inject
dna
mice
rabbit
us
fda
guidanc
dna
vaccin
conclud
preclin
studi
requir
sponsor
assess
effect
autoimmun
given
immatur
immun
system
newborn
expos
foreign
antigen
could
develop
toler
rather
protect
howev
immun
rather
toler
occur
dna
vaccin
administ
children
thu
despit
initi
concern
novelti
approach
extens
recent
evid
includ
multipl
clinic
trial
support
safeti
dna
vaccin
routin
human
prophylact
therapeut
use
tradit
adjuv
act
immun
stimul
antigen
deliveri
system
includ
kill
bacteria
bacteri
compon
aluminum
salt
oil
emuls
polysaccharid
particl
biopolym
coadminist
protein
antigen
enhanc
immunogen
detail
tradit
adjuv
compound
test
abil
enhanc
immunogen
dna
vaccin
mix
result
tabl
alum
wide
use
vaccin
adjuv
sinc
recent
studi
indic
alum
may
activ
caspas
inflammasom
contain
cytosol
receptor
flach
et
al
use
sophist
experiment
approach
atom
forc
microscopi
indic
alum
interact
directli
membran
lipid
surfac
dc
recent
studi
suggest
adjuv
effect
alum
mediat
cell
death
subsequ
releas
host
cell
dna
act
potent
endogen
immunostimulatori
signal
addit
alum
adjuv
dnaencod
hbsag
enhanc
antibodi
respons
mice
guinea
pig
nonhuman
primat
boost
hbsag
proteinprim
mice
alumadjuv
dna
vaccin
increas
product
reflect
shift
subsequ
studi
find
major
adjuv
effect
alum
combin
antigen
cmv
glycoprotein
b
gb
botulinum
neurotoxin
leishmania
mexicana
antigen
henc
use
alum
dna
vaccin
adjuv
supplant
promis
strategi
polysaccharid
sugar
molecul
surfac
mani
plant
microorgan
eg
fungi
bacteria
liposom
adjuv
may
effect
rout
oral
liposomeformul
vaccin
base
plasmid
encod
mycobacterium
tuberculosi
antigen
induc
antigenspecif
cellular
humor
mucos
immun
respons
mice
topic
administr
plasmid
dna
cation
liposom
enhanc
immunogen
hbsagencod
vaccin
signific
hurdl
need
overcom
routin
adopt
liposom
formul
includ
manag
high
rate
injectionsit
reactogen
potenti
longterm
stabil
issu
nanoparticl
base
biodegrad
polym
develop
dna
vaccin
deliveri
system
synthet
polym
poli
vinylpyridin
polylactidecoglycolid
plg
polylactidecoglycolid
acid
plga
long
histori
biocompat
safeti
human
encapsul
antigen
plg
microparticl
first
demonstr
earli
encapsul
dna
help
protect
plasmid
nucleas
degrad
provid
prolong
releas
hbsagencod
plasmid
dna
formul
plga
cetyltrimethylammonium
bromid
increas
hbsagexpress
apc
drain
lymph
node
associ
increas
antibodi
titer
tcell
immun
translat
enhanc
protect
challeng
transplant
hbsagexpress
tumor
cell
dna
vaccin
express
foot
mouth
diseas
antigen
gmcsf
formul
plg
enhanc
tcell
respons
neutral
antibodi
sheep
enhanc
protect
clinic
symptom
viremia
carrier
statu
administr
cation
plg
hiv
protein
encod
plasmid
dna
enhanc
vaccin
respons
protect
vaccin
anim
inject
plgencapsul
dna
microparticl
follow
electropor
increas
cytokin
express
recruit
apc
plasmid
antigen
express
compar
immun
plgdna
alon
tumor
antigen
encod
plasmid
dna
encapsul
biodegrad
polym
microparticl
evalu
phase
clinic
trial
cancer
patient
shown
induc
detect
immun
respons
clinic
improv
polym
nanoparticl
show
promis
therefor
dna
vaccin
adjuv
lipopolysaccharid
lp
bind
activ
induc
proinflammatori
cytokin
potent
activ
innat
immun
price
enhanc
immunogen
lp
increas
reactogen
lp
coadminist
dna
vaccin
decreas
igg
respons
dosedepend
manner
upon
intraderm
intramuscular
inject
effect
ctl
respons
plasmid
inject
gene
gun
relationship
dna
vaccin
lp
content
ctl
respons
highdos
lp
dna
vaccin
encod
increas
antitumor
respons
wherea
lowdos
lp
reduc
efficaci
vaccin
skew
respons
direct
coadministr
highdos
lp
iu
lpsmg
plasmid
dna
influenza
aencod
intraderm
dna
vaccin
enhanc
respons
high
reactogen
toxic
lp
combin
variabl
result
includ
dna
vaccin
make
unlik
candid
human
dna
vaccin
although
monophosphoryl
lipid
less
toxic
deriv
lp
retain
adjuv
activ
approv
combin
alum
sever
proteinbas
vaccin
littl
data
avail
util
dna
vaccin
adjuv
cpg
motif
known
increas
dna
vaccin
immunogen
vaccin
immunogen
reduc
methyl
cpg
motif
restor
coadministr
exogen
cpg
addit
cpg
sequenc
plasmid
backbon
cpg
motif
help
vaccin
induc
respons
addit
cpg
sequenc
plasmid
dna
target
hpv
enhanc
granzym
b
antitumor
respons
effect
enhanc
electropor
plasmid
cpg
may
also
influenc
transgen
express
vitro
deplet
cpg
associ
decreas
protein
express
note
caution
highdos
cpg
reduc
immunogen
dna
vaccin
introduc
cpg
motif
dna
vaccin
enhanc
cpg
motif
reduc
vaccin
immunogen
thu
whilst
cpg
motif
easi
design
vaccin
plasmid
unpredict
doserespons
behavior
make
less
attract
candid
human
dna
vaccin
adjuv
overal
combin
plasmid
dna
tradit
adjuv
prove
modestli
benefici
best
enhanc
dna
vaccin
immunogen
consequ
adjuv
approach
use
alum
lp
larg
supersed
dna
vaccin
use
plasmidencod
molecular
adjuv
discuss
subsequ
section
howev
still
promis
tradit
vaccin
adjuv
approach
particular
polysaccharidebas
nanoparticl
use
dna
vaccin
modul
immun
respons
induc
chemotaxi
immun
site
act
deliveri
vehicl
enhanc
plasmid
stabil
uptak
cell
aforement
clinic
trial
convent
vaccin
adjuv
dna
vaccin
detail
tabl
one
approach
boost
immunogen
dna
vaccin
consist
codeliveri
plasmid
encod
cytokin
natur
immun
stimul
tabl
administr
cytokineencod
dna
advantag
simplic
low
cost
furthermor
cytokin
express
act
site
antigen
express
therebi
avoid
toxic
system
administ
cytokin
stimul
prolifer
nk
cell
encod
dna
vaccin
increas
immun
respons
hepat
c
core
antigen
glycoprotein
bovin
diarrheal
viru
glycoprotein
nucleocapsid
sarscoronaviru
sarscov
coexpress
gene
encod
influenza
subtyp
ha
neuraminidas
bicistron
plasmid
effect
coexpress
gmcsf
protect
mice
lethal
influenza
infect
plasmid
increas
immunogen
nefand
hiv
dna
vaccin
although
effect
much
less
mark
rhesu
monkey
immun
hiv
vaccin
plasmid
encod
fusion
protein
immunoglobulin
fc
segment
effect
mice
alon
dna
vaccin
fusion
ig
increas
halflif
approxim
min
approxim
day
result
increas
memori
cell
rhesu
monkey
coimmun
plasmid
recombin
dna
vaccin
robust
cellular
respons
challeng
hiv
clinic
trial
recent
complet
evalu
safeti
vaccin
compos
plasmid
encod
variou
hiv
antigen
gagpolnefmulticlad
env
togeth
plasmid
studi
show
abil
increas
immun
respons
particularli
plasmid
administ
day
dna
immun
proinflammatori
cytokin
produc
dc
monocyt
enhanc
respons
stimul
product
coimmun
plasmid
encod
ha
enhanc
respons
mice
intranas
immun
mice
bicistron
plasmid
express
yersinia
pesti
epitop
capsular
antigen
virul
antigen
v
enhanc
mucos
iga
serum
igg
titer
v
protect
challeng
although
plasmid
express
low
level
includ
earli
clinic
trial
unsuccess
therapeut
dna
vaccin
hbv
dna
hiv
vaccin
inovio
pharmaceut
usa
target
hiv
gag
pol
env
deliv
electropor
without
profectu
bioscienc
usa
plasmid
recent
test
phase
trial
hivneg
adult
dna
vaccin
well
toler
induc
tcell
respons
specif
least
one
hiv
antigen
subject
receiv
compar
six
nine
receiv
dna
vaccin
alon
benefit
coimmun
plasmid
specif
immun
respons
induc
dna
vaccin
report
preclin
studi
switch
toward
respons
gmcsf
recruit
apc
site
immun
stimul
dc
matur
adjuv
potenti
gmcsf
coadminist
dna
extens
evalu
preclin
clinic
trial
coimmun
mice
gmcsf
pseudorabi
viru
prv
gbencod
dna
enhanc
prvspecif
antibodi
level
mainli
gener
bia
reflect
high
level
enhanc
protect
follow
prv
challeng
coimmun
rhesu
macaqu
gmcsfand
sivencod
plasmid
enhanc
humor
cellular
respons
siv
anoth
studi
rhesu
macaqu
coimmun
gmcsf
influenza
haencod
plasmid
enhanc
system
mucos
immunogen
dna
vaccin
administ
particlemedi
epiderm
deliveri
cancer
therapi
coimmun
mice
gmcsf
plasmid
induc
protect
immun
tumor
followon
studi
show
coadministr
gmcsf
protein
plasmid
patient
advanc
breast
cancer
well
toler
induc
longlast
immun
respons
anoth
clinic
trial
multipeptid
vaccin
tyrosinas
use
gmcsfencod
plasmid
adjuv
stage
iiiiv
melanoma
patient
obtain
memori
cell
subject
secret
mononuclear
cell
induc
prolifer
nk
cell
express
vector
enhanc
humor
cellular
immun
respons
gag
vaccin
mice
increas
tcell
memori
improv
tcell
memori
coimmun
plasmid
also
observ
mice
administ
dna
vaccin
encod
trypanosoma
cruzi
transsialidas
advantag
plasmid
coinject
observ
lethal
system
challeng
month
improv
protect
seen
challeng
month
express
vector
also
shown
enhanc
protect
eimeria
acevulina
prime
ctl
anim
vaccin
hbsag
dna
vaccin
increas
longev
tcell
respons
hbcag
dna
vaccin
enhanc
longterm
tcell
immun
protect
mediat
influenza
dna
vaccin
enhanc
mucos
system
immun
respons
intranas
vaccin
foot
mouth
diseas
viru
dna
vaccin
intranas
administr
express
vector
togeth
dna
vaccin
encod
hsv
glycoprotein
b
mice
enhanc
humor
immun
memori
tcell
respons
protect
challeng
recent
studi
show
coimmun
rhesu
monkey
increas
frequenc
effector
memori
cell
peripher
blood
compar
hiv
dna
vaccin
alon
human
clinic
trial
recent
undertaken
evalu
plasmid
molecular
adjuv
hiv
dna
vaccin
overal
express
vector
hold
signific
promis
futur
dna
vaccin
adjuv
great
virtu
dna
vaccin
eas
addit
molecul
cytokin
adjuv
insert
plasmid
structur
furthermor
unlik
addit
cytokin
protein
vaccin
would
extrem
limit
durat
action
owe
short
cytokin
halflif
cytokineencod
plasmid
express
cytokin
durat
antigen
therebi
provid
much
longer
immun
stimul
therefor
promis
strategi
although
human
data
approach
remain
limit
aforement
cytokineencod
dna
vaccin
adjuv
effect
variou
speci
detail
tabl
chemokin
repres
small
kda
structur
relat
molecul
regul
traffick
leukocyt
interact
subset
transmembran
gproteincoupl
receptor
chemokineencod
plasmid
evalu
abil
enhanc
dna
vaccin
detail
tabl
coadministr
gene
hiv
gagencod
plasmid
increas
activ
dc
associ
enhanc
ctl
decreas
antibodi
respons
protect
challeng
vaccinia
viru
express
gag
rant
inflammatori
chemokin
promot
accumul
activ
cell
dc
immun
mice
hbsagencod
plasmid
fuse
rant
secretori
signal
peptid
sequenc
enhanc
respons
howev
mice
receiv
coimmun
plasmid
encod
hbv
envelop
rant
show
moder
immunogen
boost
hbsag
protein
requir
maxim
respons
abil
rant
switch
respons
observ
rant
fuse
antigen
disappear
ha
rant
control
separ
promot
plasmid
suggest
enhanc
antigen
uptak
via
rant
receptor
may
contribut
respons
gener
fusion
construct
chemokin
evalu
adjuv
cancer
vaccin
vaccin
use
suppress
autoimmun
diseas
fusion
protein
hpv
protein
target
endoplasm
reticulum
led
secret
associ
enhanc
process
mhci
intraderm
immun
mice
increas
cell
associ
higher
surviv
rate
dna
alon
contribut
interact
matur
dc
naiv
cell
lymphoid
tissu
therebi
help
gener
antigenspecif
cell
coimmun
plasmid
encod
ligand
gb
prv
significantli
enhanc
product
gbspecif
cell
well
challeng
surviv
coimmun
increas
number
matur
dc
secondari
lymphoid
tissu
may
help
enhanc
prolifer
cell
benefit
coimmun
ligand
also
describ
primeboost
approach
target
gb
also
shown
enhanc
vaccin
respons
phase
studi
recent
initi
evalu
safeti
toler
therapeut
dna
vaccin
encod
antigenchemokin
fusion
plasmid
patient
lymphoplasmacyt
lymphoma
overal
seen
cytokineencod
plasmid
plasmidencod
chemokin
gene
promis
vaccin
adjuv
continu
pursu
dna
vaccin
develop
furthermor
whole
chemokin
associ
less
toxic
cytokin
henc
may
repres
better
option
cytokin
use
dna
vaccin
adjuv
upregul
costimulatori
molecul
dc
enhanc
tcell
activ
led
use
costimulatori
molecul
dna
vaccin
adjuv
tabl
costimulatori
second
signal
deliv
via
molecul
member
tnf
ligandreceptor
superfamili
among
first
costimulatori
molecul
test
vaccin
adjuv
ligand
induc
secret
cellular
prolifer
codeliveri
dna
vaccin
result
enhanc
tcell
ctl
respons
wherea
codeliveri
less
effect
bone
marrow
chimera
use
demonstr
enhanc
ctl
respons
observ
codeliveri
allow
nonbonemarrowderiv
cell
muscl
cell
act
apc
anoth
studi
codeliveri
hsv
increas
tcell
respons
protect
hsv
challeng
inject
intraderm
intramuscularli
suggest
rout
immun
import
codeliveri
primeboost
approach
target
visnamaevi
viru
result
tcell
activ
reduc
infect
success
use
adjuv
therapeut
vaccin
rheumatoid
arthriti
singl
intramuscular
inject
vaccin
encod
pseudomona
exotoxin
collageninduc
arthriti
model
increas
treg
cell
decreas
increas
respons
associ
antirheumat
activ
strategi
target
antigen
apc
encod
secret
fusion
protein
contain
extracellular
domain
dna
vaccin
encod
acceler
antibodi
respons
mice
construct
enhanc
antitumor
immun
delay
onset
mammari
cancer
similarli
fusion
streptococcu
mutan
antigen
enhanc
antibodi
respons
immun
rabbit
monkey
express
b
cell
dc
member
tnf
superfamili
respons
cellular
activ
differenti
prolifer
surviv
interact
ligand
express
cell
interact
critic
antigenstimul
bcell
develop
antibodysecret
plasma
cell
memori
b
cell
furthermor
interact
enhanc
dc
matur
requir
prime
memori
cell
codeliveri
improv
humor
immun
switch
respons
coadministr
plasmid
foot
mouth
diseas
antigen
enhanc
antibodi
respons
moreov
multimer
solubl
enhanc
cellular
respons
hiv
antigen
construct
multimer
effici
monomer
form
rankrankl
costimulatori
molecul
also
evalu
adjuv
tumor
vaccin
fail
increas
antigenspecif
ctl
respons
enhanc
tumor
protect
human
trial
use
plasmid
therapeut
vaccin
target
prostat
cancer
although
use
costimulatori
molecul
dna
vaccin
yet
extens
investig
clinic
appear
promis
strategi
requir
develop
overexpress
trif
activ
innat
immun
pathway
mice
immun
plasmid
encod
classic
swine
fever
viru
plu
trif
increas
antibodi
respons
two
three
dna
inject
anoth
studi
dualpromot
plasmid
encod
lacz
antigen
trif
show
stronger
humor
respons
wherea
triflacz
induc
strongest
cellular
immun
trifencod
plasmid
also
effect
adjuv
influenza
ha
hpv
plasmid
assess
adjuv
tat
coimmun
enhanc
tatspecif
immun
respons
bia
increas
product
ctl
respons
wherea
effect
also
investig
dna
vaccin
adjuv
coimmun
balbc
mice
gag
env
antigen
strongli
enhanc
antibodi
respons
similarli
coimmun
mice
influenza
antigen
enhanc
respons
protect
lethal
challeng
overal
use
signal
molecul
adjuv
rel
infanc
henc
unlik
impact
human
dna
vaccin
field
within
next
year
genegun
approach
genegun
techniqu
involv
bombard
skin
plasmidco
gold
particl
employ
ballist
devic
dna
deliv
directli
cell
cytoplasm
unlik
intraderm
intramuscular
inject
deliv
dna
extracellular
space
direct
deliveri
dna
cell
allow
use
small
amount
plasmid
dna
induc
immun
respons
compar
classic
dna
inject
avian
murin
model
influenza
vaccin
requir
less
dna
deliv
gene
gun
compar
direct
intraderm
inject
induct
cellular
humor
immun
mice
human
immun
respons
induc
gene
gun
show
bia
potenti
due
low
amount
cpg
plasmid
use
howev
limit
genegun
approach
mean
longer
develop
human
dna
deliveri
electropor
emerg
favor
technolog
deliveri
dna
vaccin
anim
electropor
use
electr
stimul
muscl
tissu
presenc
plasmid
dna
transient
permeabil
cell
membran
improv
effici
transfect
tcell
migrat
electropor
enhanc
dna
vaccin
efficaci
achiev
respons
compar
protein
vaccin
electropor
enhanc
vaccin
respons
larg
anim
macaqu
sheep
pig
previous
show
poor
dna
vaccin
efficaci
recent
review
cite
ten
phase
iii
clinic
trial
involv
electropor
phase
dose
escal
trial
plasmid
electropor
carri
metastat
melanoma
twenti
four
patient
treat
seven
dose
level
common
advers
effect
pain
electropor
subject
bleed
inject
site
patient
grade
one
grade
two
bleed
trend
toward
treatment
effect
tumor
lesion
demonstr
necrosi
anoth
phase
iii
clinic
trial
conduct
recurr
prostat
cancer
electropor
enhanc
humor
cellular
immun
preliminari
data
ongo
clinic
trial
show
electropor
enhanc
frequenc
magnitud
tcell
respons
review
compani
tri
commerci
electropor
technolog
tri
downplay
neg
electropor
consider
barrier
adopt
includ
pain
discomfort
procedur
unwieldi
costli
devic
difficulti
ensur
intramuscular
inject
obes
subject
given
associ
sever
discomfort
electropor
like
unsuit
use
prophylact
vaccin
henc
major
market
like
therapeut
context
includ
cancer
vaccin
recent
noninvas
electropor
combin
intraderm
inject
plasmid
dna
evalu
nonhuman
primat
longlast
express
antigen
induct
tcell
respons
discomfort
intraderm
electropor
said
less
intramuscular
electropor
although
whether
reduct
suffici
make
technolog
accept
prophylact
vaccin
set
yet
seen
sever
studi
evalu
dna
vaccin
use
needlefre
deliveri
system
biojector
bioject
medic
technolog
usa
method
plasmid
dna
solut
spray
skin
effort
directli
transfect
langerhan
cell
much
way
earlier
genegun
approach
studi
nonhuman
primat
show
increas
dna
immunogen
use
biojector
devic
compar
use
convent
syring
howev
clinic
trial
use
biojector
devic
inject
dna
ongo
recent
excit
data
present
enhanc
dna
vaccin
respons
obtain
new
needlefre
intraderm
deliveri
devic
made
pharmajet
royal
pharmajet
inc
per
comm
indic
promis
area
futur
develop
mani
pathogen
eg
hiv
influenza
streptococcu
pneumonia
infect
mucos
surfac
mucos
vaccin
may
major
advantag
prevent
diseas
variou
adjuv
carrier
deliveri
system
evalu
mucos
immun
includ
particlemedi
deliveri
system
liposom
cytokineencod
dna
cpg
oligodeoxynucleotid
dctarget
dna
primeboost
approach
bacteri
vector
use
bacteri
vector
promis
approach
allow
specif
target
activ
apc
pathogenassoci
molecular
pattern
receptor
exampl
immun
salmonella
typhimurium
carri
dna
plasmid
encod
glycoprotein
b
result
strong
system
vagin
tcell
respons
confer
protect
hsv
vagin
challeng
particlemedi
deliveri
system
also
use
deliv
plasmid
dna
mucos
surfac
formul
haencod
plasmid
polyethylenimin
improv
effici
transfect
respiratori
tract
follow
intranas
administr
luciferasecod
dna
high
level
haspecif
iga
observ
bronchoalveolar
lavag
serum
heterolog
primeboost
strategi
show
promis
mucos
immun
exampl
combin
intranas
protein
boost
initi
prime
envencod
intramuscular
dna
vaccin
result
signific
enhanc
humor
cellular
immun
respons
hiv
efficaci
intramuscular
versu
intranas
siv
dnaprim
sivmvaboost
immun
test
prevent
diseas
progress
intrarect
siv
challeng
rhesu
macaqu
nasal
immun
result
higher
persist
sivspecif
rectal
iga
respons
mucos
tcell
respons
intramuscular
immun
follow
challeng
nasal
vaccin
anim
greater
preserv
circul
colorect
cell
longer
diseasefre
interv
signific
correl
cell
day
challeng
control
viremia
week
mucos
deliveri
dna
also
use
intramuscular
intraderm
immun
induc
higher
mucos
immun
hiv
nevertheless
mucos
administr
dna
vaccin
rel
immatur
technolog
yet
test
clinic
therefor
even
ultim
success
unlik
make
impact
human
dna
vaccin
within
next
year
vaccin
strategi
base
primeboost
regimen
enhanc
respons
difficult
pathogen
hiv
malaria
strategi
involv
prime
immun
respons
use
antigen
express
first
vector
typic
plasmid
dna
follow
boost
administr
antigen
differ
vector
typic
recombin
viru
common
vector
includ
adenoviru
fowlpox
vaccinia
viru
heterolog
immun
often
show
strong
synergist
effect
compar
homolog
immun
clinic
trial
dnaprim
boost
induc
cell
hiv
dnaprim
mvaboost
strategi
similarli
enhanc
immun
hiv
recent
dna
primepoxviru
boost
nivac
approach
target
evalu
phase
trial
two
dna
follow
two
poxvirusboost
inject
induc
polyfunct
durabl
tcell
respons
env
respons
higher
heterolog
dnanivac
compar
homolog
nivacnivac
regimen
extens
effort
made
develop
optim
primeboost
malaria
vaccin
base
prime
dna
viral
vector
follow
boost
rang
recombin
viral
vector
includ
mva
fowlpox
adenoviru
primeboost
strategi
dna
boost
metrap
mva
multipl
epitopethrombospondinrel
adhes
protein
reduc
malaria
parasit
burden
liver
compar
homolog
immun
delay
parasitemia
reduc
mortal
follow
sporozoit
challeng
substitut
plasmid
dna
prime
fowlpox
viru
elicit
steril
protect
two
five
volunt
persist
memori
cell
observ
month
dnaprim
proteinboost
strategi
target
malaria
csp
induc
antibodi
tcell
respons
clinic
recent
studi
dna
prime
follow
boost
target
hiv
gag
success
induc
gagspecif
tcell
respons
dnaprim
proteinboost
strategi
also
test
use
inactiv
recombin
protein
antigen
dna
prime
env
follow
intramuscular
protein
boost
formul
advax
polysaccharid
adjuv
significantli
enhanc
humor
cellular
immun
respons
hiv
env
protein
use
dna
vaccin
prime
follow
proteinor
vectorbas
boost
strategi
highli
promis
provid
best
world
term
prime
strong
tcell
respons
time
maxim
neutral
antibodi
respons
furthermor
combin
adjuv
protein
boost
strategi
approach
face
minim
regulatori
hurdl
individu
dna
protein
compon
known
safe
well
toler
problem
would
anticip
combin
approach
essenti
plasmid
featur
dna
vaccin
includ
strong
promot
optim
express
mammalian
cell
select
marker
polyadenyl
polya
sequenc
stabil
transcript
addit
sinc
optim
express
gene
depend
splice
transcript
inclus
intron
promoterenhanc
complex
may
improv
express
approach
increas
transcript
translat
may
therebi
improv
dna
vaccin
immunogen
human
achiev
optim
transcript
element
plasmid
backbon
promot
import
compon
plasmid
drive
express
gene
interest
classic
promot
dna
vaccin
includ
human
cmvimmedi
earli
actin
cagg
promot
cmv
promot
use
dna
vaccin
sinc
drive
high
constitut
express
level
wide
rang
mammalian
tissu
suppress
downstream
readthrough
improv
express
immunogen
observ
modifi
cmv
promot
ie
incorpor
downstream
cmv
promot
use
chimer
promot
altern
cmv
promot
includ
host
tissuespecif
promot
avoid
constitut
express
antigen
inappropri
tissu
gener
result
lower
immunogen
presenc
intron
vector
backbon
downstream
promot
enhanc
stabil
mrna
increas
gene
express
kozak
sequenc
immedi
prior
atg
start
codon
may
enhanc
antigen
express
use
speciesspecif
codon
increas
antigen
express
may
therebi
enhanc
dna
vaccin
immunogen
gene
express
manipul
alter
polya
sequenc
requir
proper
termin
transcript
export
mrna
nucleu
mani
current
dna
vaccin
use
bovin
hormon
termin
sequenc
alter
polya
sequenc
may
enhanc
gene
express
dna
vaccin
therebi
immun
respons
henc
optim
plasmid
design
dna
vaccin
combin
bacteri
eukaryot
element
vector
design
allow
high
copi
number
product
high
mammalian
express
therebi
ensur
maxim
immunogen
dna
vaccin
promis
altern
approach
tradit
protein
vaccin
prevent
treatment
infecti
diseas
cancer
allergi
howev
dna
vaccin
prove
effect
anim
model
continu
suffer
suboptim
human
immunogen
henc
major
frustrat
dna
vaccin
field
inabl
predict
human
vaccin
respons
base
mous
immunogen
data
mean
quantit
differ
observ
differ
dna
vaccin
approach
mice
rare
translat
human
exampl
electropor
cytokin
adjuv
may
deliv
improv
antibodi
titer
mice
may
deliv
best
twoto
threefold
improv
titer
human
thu
small
anim
model
typic
use
adjuv
comparison
studi
like
mislead
inform
instead
field
would
advis
use
larg
anim
model
best
human
undertak
adjuv
comparison
studi
henc
major
advanc
dna
vaccin
design
move
closer
true
potenti
human
use
headtohead
human
compar
studi
differ
dna
vaccin
technolog
requir
enabl
select
effect
technolog
given
diseas
improv
made
plasmid
construct
codon
optim
remov
cryptic
splice
site
use
molecular
adjuv
electropor
intraderm
needlefre
inject
heterolog
primeboost
strategi
among
recent
promis
advanc
use
cytokin
chemokin
costimulatori
molecul
molecular
adjuv
dna
vaccin
combin
strategi
enhanc
antigen
express
electropor
intraderm
needleless
inject
molecular
adjuv
approach
potenti
significantli
enhanc
dna
vaccin
immunogen
larg
number
ongo
human
clinic
trial
dna
vaccin
testament
belief
dna
vaccin
ultim
deliv
potenti
given
regulatori
challeng
like
first
dna
vaccin
breakthrough
area
therapeut
vaccin
cancer
infecti
diseas
applic
follow
much
later
reflect
fact
cancer
indic
current
repres
largest
group
human
dna
vaccin
trial
realiz
full
potenti
dna
vaccin
ongo
need
research
mechan
action
particular
strategi
enhanc
immunogen
research
allow
one
human
therapeut
cancer
dna
vaccin
achiev
licensur
within
next
year
good
safeti
record
human
studi
abil
induc
humor
cellular
respons
provid
immun
prime
poor
immun
boost
dna
vaccin
offer
advantag
convent
protein
vaccin
term
flexibl
rapid
manufactur
low
cost
abil
induc
cellular
immun
sever
dna
vaccin
licens
veterinari
applic
almost
phase
ii
clinic
trial
confirm
safeti
dna
vaccin
human
suboptim
immunogen
ongo
barrier
human
dna
vaccin
strategi
enhanc
dna
vaccin
efficaci
includ
adjuv
codon
optim
electropor
intraderm
deliveri
optim
dna
vaccin
get
closer
level
immunogen
requir
human
use
greater
understand
mechan
dna
vaccin
action
requir
antigen
sequenc
obtain
follow
isol
pathogen
step
follow
identif
sequenc
step
sequenc
interest
amplifi
pcr
gener
chemic
synthesi
dna
sequenc
clone
multipl
clone
site
eukaryot
plasmid
follow
enzymat
reaction
step
compet
bacteria
transform
construct
plasmid
grown
specif
media
step
ultrapur
plasmid
obtain
use
anionexchang
column
follow
cell
lysi
step
plasmid
formul
convent
adjuv
coadminist
genet
adjuv
step
plasmid
deliv
inocul
site
intraderm
subcutan
topic
intramuscularli
step
follow
intramuscular
inject
muscl
cell
main
transfect
cell
resid
apc
also
directli
transfect
plasmid
plasmid
enter
nucleu
transfect
cell
initi
gene
transcript
step
antigen
protein
produc
cytoplasm
submit
posttransl
modif
similarli
nativ
protein
natur
infect
apc
also
activ
crossprim
follow
captur
antigen
secret
muscl
cell
captur
apoptot
muscl
cell
load
antigen
apc
migrat
proxim
lymph
node
present
antigen
peptid
cell
via
mhcii
tcell
receptor
cell
mhci
tcell
receptor
step
activ
cell
trigger
differenti
specif
b
cell
also
activ
secret
antigen
arriv
lymph
node
prime
lymphocyt
cell
b
cell
could
restimul
expand
immun
site
present
peptidemhc
complex
display
transfect
muscl
cell
step
thu
dna
vaccin
induc
humor
cellular
immun
respons
specif
microbi
antigen
tlr
tolllik
receptor
tabl
exampl
dna
vaccin
trial
use
convent
adjuv
ref
aluminum
salt
hbv
im
mice
guinea
pig
rhesu
macaqu
increas
antibodi
respons
mice
guinea
pig
rhesu
macaqu
cmv
im
increas
antibodi
respons
polysaccharid
hiv
im
combin
dna
vaccin
prime
sequenti
adjuv
protein
boost
via
im
rout
enhanc
mucos
system
immun
abl
neutral
homolog
strain
hiv
vaxfectin
increas
immunogen
dna
vaccin
provid
effect
protect
challeng
im
induc
hi
titer
healthi
volunt
fourfold
rise
baselin
subject
induct
hemagglutinin
tcell
respons
volunt
mice
induct
mucos
cellular
humor
immun
respons
cation
transfersom
hbv
topic
mice
induct
antibodi
respons
higher
compar
convent
im
vaccin
synthet
polym
plgplga
hbv
im
increas
antibodi
respons
ctl
respons
secret
immun
protect
tumor
im
induc
immun
respons
correl
clinic
benefit
ep
mice
ep
increas
antigen
express
robust
tcell
respons
hiv
oral
mice
prolong
express
antigen
lymphoid
tissu
induct
system
mucos
respons
expert
rev
vaccin
author
manuscript
avail
pmc
decemb
enhanc
granzym
b
antitumor
vaccin
effect
potenti
use
ep
lcmv
im
improv
immun
respons
protect
lethal
viral
infect
ctl
cytotox
cell
dth
delayedtyp
hypersensit
ep
electropor
hi
hemagglutin
inhibit
im
intramuscular
intranas
lcmv
lymphocyt
choriomening
viru
lp
lipopolysaccharid
plg
polylactidecoglycolid
plga
polylactidecoglycolid
acid
tlr
tolllik
receptor
tabl
exampl
chemokin
costimulatori
adjuv
ref
hiv
im
enhanc
ctl
respons
protect
inject
plasmid
encod
day
inject
plasmid
encod
gag
improv
ctl
respons
protect
hiv
im
signific
benefit
note
rant
hbv
im
increas
humor
cellular
respons
influenza
gene
gun
mice
switch
respons
hpv
id
linkag
induc
secret
chemoattract
fusion
protein
induc
cell
confer
resist
cancer
coimmun
increas
system
igg
mucos
iga
respons
specif
cell
secret
improv
protect
challeng
costimulatori
molecul
mice
increas
acceler
antibodi
respons
improv
protect
challeng
cancer
im
mous
tumor
model
induc
protect
immun
delay
onset
cancer
streptococcu
mutan
im
rabbit
rhesu
macaqu
increas
system
mucos
antibodi
respons
hbv
im
increas
antibodi
respons
hiv
im
enhanc
tcell
respons
ctl
cytotox
cell
dth
delayedtyp
hypersensit
id
intraderm
im
intramuscular
intranas
expert
rev
vaccin
author
manuscript
avail
pmc
decemb
